Drug Discovery Outsourcing Market Report 2026

The drug discovery outsourcing market size has grown strongly in recent years. It will grow from $4.24 billion in 2025 to $4.57 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to rising complexity of drug development pipelines, increasing r&d cost pressures, expansion of biotechnology startups, growing demand for specialized scientific expertise, increasing reliance on external research partners.

The drug discovery outsourcing market size is expected to see strong growth in the next few years. It will grow to $6.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing adoption of ai-enabled drug discovery tools, rising focus on rare and complex disease research, expansion of personalized medicine development, growing investment in outsourced innovation models, increasing globalization of pharmaceutical r&d. Major trends in the forecast period include increasing adoption of integrated drug discovery service models, rising demand for end-to-end preclinical outsourcing, growing use of advanced screening platforms, expansion of specialized cro capabilities, enhanced focus on accelerated development timelines.

The increasing prevalence of chronic diseases is anticipated to drive the expansion of the drug discovery outsourcing market in the coming years. Chronic diseases are long-term health conditions that persist over extended periods, often lasting for many years or throughout an individual’s lifetime. The rise in chronic diseases is attributed to factors such as an aging population, lifestyle-related behaviors, urbanization, and environmental influences. Drug discovery outsourcing supports the faster development of treatments for chronic conditions by offering access to specialized expertise and advanced technologies, while also reducing development timelines and costs. For example, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a U.S.-based federal health agency, approximately 194 million U.S. adults (76.4%) reported having one or more chronic conditions in 2023, and about 130 million adults (51.4%) reported having multiple chronic conditions. Therefore, the rising prevalence of chronic diseases is fueling the growth of the drug discovery outsourcing market.

Leading companies in the drug discovery outsourcing market are concentrating on the development of innovative solutions, such as digital health technologies, to better address the needs of healthcare professionals, regulatory authorities, and patients. Digital health solutions include technologies and services such as telemedicine platforms, mobile health applications, and wearable devices that improve healthcare delivery, patient engagement, and overall health management. For instance, in November 2023, AstraZeneca PLC, a UK-based biopharmaceutical company, introduced Evinova, an advanced health technology business focused on driving innovation in the life sciences sector and improving clinical trial delivery. The initiative aims to provide globally scalable digital products and services that have already demonstrated effectiveness in AstraZeneca’s clinical trials across more than 40 countries. By enhancing clinical trial design and execution, Evinova seeks to streamline the development of new medicines, ultimately lowering both time and cost requirements.

In July 2024, Selvita SA, a Poland-based provider of drug discovery, research, and development services, acquired PozLab for an undisclosed amount. This strategic acquisition substantially strengthens Selvita’s drug development capabilities, positioning the company as a comprehensive solutions provider within the pharmaceutical industry and enabling the delivery of small-molecule drug manufacturing services for early-stage clinical trials. PozLab is a Poland-based contract development organization offering end-to-end pharmaceutical development services.

Major companies operating in the drug discovery outsourcing market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Eurofins SE, Charles River Laboratories, QIAGEN N.V., Curia Global Inc., EVOTEC, Pharmaron Beijing Co. Ltd., Genscript Biotech, WuXi AppTec, Pharmaceutical Product Development, LLC, Syngene International Limited, Jubilant Biosys, Dalton Pharma Services, Oncodesign Services, DiscoverX Corp., Domainex Ltd., Exscientia, TCG Lifesciences Pvt Ltd., GVK Biosciences Private Limited.

North America was the largest region in the drug discovery outsourcing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug discovery outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug discovery outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the drug discovery outsourcing market by increasing costs of imported laboratory instruments, analytical equipment, reagents, consumables, and specialized testing materials used across chemistry and biological services. Contract research organizations in North America and Europe are particularly affected due to dependence on imported scientific equipment, while Asia-Pacific faces cost pressure on export-oriented research services. These tariffs are raising operational expenses and influencing pricing structures for outsourced projects. However, they are also encouraging regional sourcing of laboratory supplies, expansion of local research infrastructure, and diversification of service delivery locations to improve long-term resilience.

The drug discovery outsourcing market research report is one of a series of new reports that provides drug discovery outsourcing market statistics, including drug discovery outsourcing industry global market size, regional shares, competitors with a drug discovery outsourcing market share, detailed drug discovery outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery outsourcing industry. This drug discovery outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug discovery outsourcing refers to the practice in which pharmaceutical companies contract external organizations to carry out different stages of the drug discovery process - such as target identification, lead optimization, and preclinical testing - in order to access specialized expertise, reduce costs, and shorten development timelines.

The primary categories of drug discovery outsourcing include chemistry services and biological services. Chemistry services involve providing specialized chemical expertise, including the synthesis, analysis, and optimization of drug candidates. The workflow encompasses target identification and screening, target validation and functional informatics, lead identification and candidate optimization, preclinical development, and other related processes. Disease models used in these services include in vitro models, animal models, cellular models, and others. These services support a wide range of therapeutic areas, including cardiovascular, central nervous system (CNS), gastrointestinal, hematology, respiratory, infectious diseases, oncology, immunology, and more. End users include pharmaceutical and biotechnology companies, academic institutions, and other research organizations.

The drug discovery outsourcing market includes revenues earned by entities by providing services such as trial design, site management, patient recruitment, and data collection and analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.